Develops genetic tests for rare diseases.
Jun 2026Revenue $454M/yrExpenses $547M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will GeneDx Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $454M and expenses $547M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $428M | $441M | −$13.1M |
| Dec 2024 | $305M | $329M | −$23.2M |
| Dec 2023 | $203M | $383M | −$181M |
| Dec 2022 | $235M | $902M | −$668M |
| Dec 2021 | $212M | $658M | −$446M |
| Dec 2020 | $179M | $421M | −$242M |
| Dec 2019 | $196M | $227M | −$30.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.